Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from Chardan Capital

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $212.00 price target on the stock. Chardan Capital’s price target indicates a potential upside of 29.55% from the stock’s previous close.

KRYS has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday. Stifel Nicolaus upped their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Citigroup upped their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Down 5.6 %

Shares of NASDAQ KRYS opened at $163.64 on Thursday. The stock has a market capitalization of $4.71 billion, a P/E ratio of 92.45 and a beta of 0.80. The firm’s 50-day moving average price is $181.54 and its two-hundred day moving average price is $184.87. Krystal Biotech has a 52-week low of $107.50 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the firm posted ($0.67) EPS. Krystal Biotech’s quarterly revenue was up 879.9% compared to the same quarter last year. As a group, equities research analysts expect that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. EFG Asset Management North America Corp. boosted its holdings in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after buying an additional 60 shares during the period. Nisa Investment Advisors LLC boosted its stake in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System grew its position in Krystal Biotech by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after purchasing an additional 108 shares in the last quarter. Fiera Capital Corp grew its position in Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after purchasing an additional 130 shares in the last quarter. Finally, KBC Group NV raised its stake in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after purchasing an additional 132 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).